Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal

All NewsMarch 31, 2026

Apellis surges after Biogen’s $5.6 billion buyout at $41 per share, adding complement therapies and boosting long-term EPS outlook.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent